What is the antidote for rivaroxaban and what are the recommended dosing regimens for severe or life‑threatening bleeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Rivaroxaban Antidote for Life-Threatening Bleeding

Andexanet alfa is the specific FDA-approved antidote for rivaroxaban-associated life-threatening bleeding, administered as either a low-dose regimen (400 mg IV bolus followed by 480 mg infusion over 2 hours) or high-dose regimen (800 mg IV bolus followed by 960 mg infusion over 2 hours), depending on the timing and dose of the last rivaroxaban intake. 1, 2, 3

Dosing Algorithm for Andexanet Alfa

Low-dose regimen (400 mg bolus + 480 mg infusion):

  • Last rivaroxaban dose ≥8 hours prior 2
  • Last rivaroxaban dose ≤10 mg taken <8 hours prior or timing unknown 2

High-dose regimen (800 mg bolus + 960 mg infusion):

  • Last rivaroxaban dose >10 mg taken <8 hours prior or timing unknown 1, 2
  • Unknown dose of rivaroxaban taken <8 hours prior 2

The bolus is administered at 30 mg/min for high dose or over 15 minutes for low dose, followed by continuous infusion at 8 mg/min or 4 mg/min respectively for up to 120 minutes. 1, 2, 3

Mechanism and Efficacy

Andexanet alfa is a modified recombinant factor Xa decoy protein that binds rivaroxaban with high affinity, preventing it from inhibiting endogenous factor Xa. 1, 4 In the ANNEXA-4 study, andexanet alfa reduced anti-factor Xa activity by 92-93% within minutes of administration, with 82% of patients achieving good or excellent hemostasis at 12 hours. 1, 3

Alternative Strategy: 4-Factor Prothrombin Complex Concentrate

When andexanet alfa is unavailable, administer 4-factor PCC at 50 U/kg IV (maximum 4,000 units). 2, 5 The 2024 World Society of Emergency Surgery guidelines recommend weight-based dosing: 1,500 units for patients <65 kg or 2,000 units for patients >65 kg. 1

Four-factor PCC increases prothrombin and factor X levels, inducing a compensatory pro-hemostatic effect through increased thrombin generation potential. 1 A 2019 study demonstrated that 4-factor PCC achieved clinical hemostasis in 72.4% of patients with rivaroxaban-associated major bleeding. 6

Adjunctive Measures

For recent ingestion (<2-4 hours):

  • Administer activated charcoal to reduce absorption 7, 2, 8
  • This is particularly effective if given within 3 hours of the last dose 8

Supportive measures:

  • Discontinue rivaroxaban immediately 9
  • Provide hemodynamic support and blood product transfusion as needed 9, 10
  • Consider tranexamic acid as adjunctive therapy to support hemostasis 4, 5

Laboratory Assessment

Anti-factor Xa activity assays are preferred for quantifying rivaroxaban levels, with a threshold >50 ng/mL considered clinically significant for serious bleeding. 4, 11 Prothrombin time (PT) using rivaroxaban-sensitive reagents can provide qualitative assessment. 12

Do not use PT, INR, aPTT, or anti-FXa activity to monitor the effectiveness of PCCs when used for reversal. 2

Critical Safety Considerations

Thrombotic events occur in approximately 10% of patients within 30 days of receiving andexanet alfa. 4, 11, 13 The reversal effect is transient, with anti-factor Xa activity returning toward baseline approximately 2 hours after infusion completion. 4, 11

Rivaroxaban is not dialyzable due to high plasma protein binding (92-95%), except in specific circumstances. 9, 8

Common Pitfalls to Avoid

  • Do not use prophylactic hemostatic agents for emergency surgery even with high rivaroxaban concentrations present 12, 10
  • Do not use fresh frozen plasma as it is ineffective for reversing direct factor Xa inhibitors 8
  • Do not use platelet transfusion or desmopressin as there is no evidence supporting their use for DOAC-associated bleeding 8
  • Andexanet alfa has not been studied in patients requiring urgent surgery and is not approved for this indication 1

Pediatric Considerations

For younger children with major bleeding on rivaroxaban, hold the medication and consider 3- or 4-factor PCC. 7 Andexanet alfa can be considered in older adolescents with major bleeding, though there are no pediatric studies. 7 Activated charcoal should be considered if the last dose was within 2 hours. 7

References

Guideline

Reversal of Apixaban

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Reversal of Apixaban with Kcentra

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Reversal of Apixaban in Life-Threatening Bleeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Rivaroxaban and hemostasis in emergency care.

Emergency medicine international, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.